AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A polynucleotide directed towards a gene of a catalytic subunit of human telomerase,
characterized in that
the polynucleotide specifically interacts with the mRNA of the catalytic subunit of human telomerase in at least two target sequence regions, 2176 to 2250 and 2296 to 2393, in accordance with accession number AF015950.

2. (Currently Amended) The polynucleotide according to claim 1,
~~characterized in that~~ wherein
the polynucleotide interacts with target sequence regions selected from the group comprising 2183-2205, 2206-2225, 2315-2334, 2317-2336, 2324-2346, 2331-2350 and/or 2333-2352.

3. (Currently Amended) The polynucleotide according to ~~any of~~ claims 1 ~~and 2~~,
~~characterized in that~~ wherein
the sequence region and/or the polynucleotide is modified by addition, amplification, inversion, missense mutation, nonsense mutation, point mutation, deletion and/or substitution.

4. (Currently Amended) The polynucleotide according to ~~any of~~ claims 1 ~~to 3~~,
~~characterized in that~~ wherein
the polynucleotide is immobilized.

5. (Currently Amended) The polynucleotide according to ~~any of~~ claims 1 ~~to 4~~,
~~characterized in that~~ wherein
the polynucleotide is a nucleic acid construct or a derivative thereof.

6. (Currently Amended) The polynucleotide according to claim 5, ~~characterized in that~~ wherein
the polynucleotide is fused or complexed with another molecule supporting the directed transport to the target site, the uptake in and/or distribution inside a target cell.

7. (Currently Amended) The polynucleotide according to claim 5 ~~or 6~~, ~~characterized in that~~ wherein
the nucleic acid construct is an antisense oligonucleotide, a DNAzyme, a peptide nucleic acid, a ribozyme and/or an siRNA.

8. (Currently Amended) The polynucleotide according to claim 7, ~~characterized in that~~ wherein
the antisense oligonucleotide is modified by phosphothioate bonds and/or other chemical modifications.

9. (Currently Amended) The polynucleotide according to ~~any of~~ claims 1 ~~to 8~~, ~~characterized in that~~ wherein
the sequence region of the hTERT-mRNA, to which the polynucleotide is complementary, is selected from the group comprising 2183-2205, 2206-2225, 2315-2334, 2317-2336, 2324-2346, 2331-2350 and/or 2333-2352.

10. (Currently Amended) A pharmaceutical composition comprising a polynucleotide according to ~~any of~~ claims 1 ~~to 9 alone or~~ in combination with a pharmaceutically tolerable carrier.

11. (Currently Amended) A kit comprising:
a polynucleotide according to ~~any of~~ claims 1 ~~to 9~~ and/~~or~~ a pharmaceutically ~~composition according to claim 10~~ tolerable carrier.

12. Canceled.

13. (Currently Amended) ~~Use of a polynucleotide according to any of claims 1 to 9, a pharmaceutical composition according to claim 10, a kit according to claim 11 and/or an array according to claim 12 in~~ Method for diagnosis, prophylaxis, therapy, follow-up and/or aftercare of diseases associated with cell growth, differentiation and/or division, comprising using a polynucleotide according to claim 1, optionally in combination with a pharmaceutically tolerable carrier.

14. (Currently Amended) The ~~use~~ method according to the preceding claim, ~~characterized in that~~ wherein
the disease is a tumor.

15. (Currently Amended) The ~~use~~ method according to ~~the preceding claim~~ claim 14,
~~characterized in that~~ wherein
the tumor is a solid tumor or a leukemia.

16. (Currently Amended) The ~~use~~ method according to ~~the preceding claim~~ claim 15,
~~characterized in that~~ wherein
the solid tumor is a tumor of the urogenital tract and/or gastrointestinal tract.

17. Canceled.

18. Canceled.

19. (Currently Amended) The ~~use~~ method according to claim 16,
~~characterized in that~~ wherein
the tumor of the urogenital tract is a bladder carcinoma and/or a metastase of said tumor.

20. (Currently Amended) The ~~use~~ method according to claim 13,
~~characterized in that~~ wherein
the follow-up is monitoring the effectiveness of an anti-tumor treatment.

21. (Currently Amended) The ~~use~~ method according to ~~any of~~ claims 13 ~~to 20~~, ~~characterized in that~~ wherein
the polynucleotide is used in a combination therapy.

22. Canceled.

23. (Currently Amended) The ~~use~~ method according to ~~the preceding~~ claim 22, ~~characterized in that~~ wherein
the combination therapy ~~is~~ comprises an adjuvant biologically specified form of therapy.

24. (Currently Amended) The ~~use~~ method according to ~~the preceding~~ claim 23, ~~characterized in that~~ wherein
said form of therapy is an immune therapy.

25. (Currently Amended) The ~~use~~ method according to ~~any of~~ claims 21 ~~to 24~~, ~~characterized in that~~ wherein
the combination therapy is a gene therapy and/or a therapy using a polynucleotide against the same or other target molecule.

26. (Currently Amended) The ~~use~~ method according to ~~any of~~ claims 13 ~~to 25~~ for increasing the sensitivity of tumor cells to cytostatic agents and/or radiation.

27. (Currently Amended) ~~Use of a polynucleotide according to any of claims 1 to 9 and/or according to any of claims 13 to 26~~ Method for inhibiting the vitality, the proliferation rate of cells, for inducing apoptosis and/or cell cycle arrest, comprising the step of using a polynucleotide according to claim 1.